3-Jan-2025
No headlines found.
Globe Newswire (Thu, 14-Nov 7:00 AM ET)
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
Globe Newswire (Tue, 5-Nov 7:00 AM ET)
Business Wire (Mon, 28-Oct 8:21 AM ET)
Globe Newswire (Wed, 23-Oct 8:00 AM ET)
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Globe Newswire (Mon, 7-Oct 8:00 AM ET)
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Nuvectis Pharma trades on the NASDAQ stock market under the symbol NVCT.
As of January 3, 2025, NVCT stock price climbed to $5.58 with 178,763 million shares trading.
NVCT has a beta of 3.18, meaning it tends to be more sensitive to market movements. NVCT has a correlation of 0.10 to the broad based SPY ETF.
NVCT has a market cap of $107.81 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that NVCT belongs to (by Net Assets): VTI, VXF, IWC.
NVCT has underperformed the market in the last year with a return of -32.6%, while the SPY ETF gained +27.8%. In the last 3 month period, NVCT fell short of the market, returning -9.4%, while SPY returned +4.6%. However, in the most recent 2 weeks NVCT has outperformed the stock market by returning +23.5%, while SPY returned +0.1%.
NVCT support price is $5.10 and resistance is $5.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVCT shares will trade within this expected range on the day.